SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After US FDA Trial Clearance For Pulmonary Fibrosis Drug
CSPC Pharmaceutical Group (SEHK:1093) just received U.S. FDA clearance to start clinical trials for SYH2059, an inhaled PDE4B inhibitor for pulmonary fibrosis, highlighting its respiratory pipeline on an international stage.
See our latest analysis for CSPC Pharmaceutical Group.
That FDA green light comes after a series of fresh trial approvals in China for hemophilia and asthma treatments. It also arrives as CSPC Pharmaceutical Group’s 90 day share price return of 25.10% and 1 year total...